Pancreatic Cancer Research

ResearcherMOLIT Institut für Personalisierte MedizinActive in the last 2 years

Uwe M. Martens

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0001-7999-4359; OpenAlex author ID A5017172335. Sources: OpenAlex.

Their work

Papers
8 (first author 0, last author 2)
Trials
0
Grants
0
Labs led
0
Collaborators
33
Papers, trials and grants by year

2017: 1 paper · 2018: 1 paper · 2019: none · 2020: none · 2021: 1 paper · 2022: 1 paper · 2023: none · 2024: 2 papers · 2025: none · 2026: 2 papers

Papers 8

  1. Growth differentiation factor-15 (GDF-15) in localized pancreatic adenocarcinoma treated with multiagent chemotherapy: a biomarker analysis from the NEOLAP tri… Co-author DOI 10.1016/j.esmogo.2025.100274↗
  2. Minimal residual disease assessment through ctDNA facilitates tailored immunotherapy in MSI-high, NTRK1-fusion pancreatic adenocarcinoma. Last author DOI 10.1093/oncolo/oyag108↗
  3. Corrigendum to "Prognostic and predictive value of CA 19-9 in locally advanced pancreatic cancer treated with multiagent induction chemotherapy: results from a… Co-author DOI 10.1016/j.esmoop.2024.103463↗
  4. Corrigendum to "Prognostic and predictive value of CA 19-9 inlocally advanced pancreatic cancer treated with multiagent induction chemotherapy: results from a … Co-author DOI 10.1016/j.esmoop.2024.103705↗
  5. Prognostic and predictive value of CA 19-9 in locally advanced pancreatic cancer treated with multiagent induction chemotherapy: results from a prospective, mu… Co-author DOI 10.1016/j.esmoop.2022.100552↗
  6. Nab-paclitaxel plus gemcitabine versus nab-paclitaxel plus gemcitabine followed by FOLFIRINOX induction chemotherapy in locally advanced pancreatic cancer (NEO… Co-author DOI 10.1016/s2468-1253(20)30330-7↗
  7. Sustainable Response of a Patient With Metastasized Pancreatic Cancer and a Hypermutational Phenotype to Immunotherapy. New Therapeutic Concept for a Rare Subt… Last author DOI 10.1200/po.18.00005↗
  8. Phase I/II Study of Refametinib (BAY 86-9766) in Combination with Gemcitabine in Advanced Pancreatic cancer. Co-author DOI 10.1007/s11523-016-0469-y↗

Closest collaborators

The 25 strongest of 33 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Ingo Hartlapp · 5 shared papers, 2021–2026 · strength 0.76
  2. Frank Kullmann · 5 shared papers, 2021–2026 · strength 0.76
  3. Volker Kunzmann · 5 shared papers, 2021–2026 · strength 0.76
  4. Thomas Jens Ettrich · 5 shared papers, 2021–2026 · strength 0.76
  5. Volker Heinemann · 5 shared papers, 2021–2026 · strength 0.76
  6. Jens Thomas Siveke · 5 shared papers, 2021–2026 · strength 0.76
  7. Hana Algül · 5 shared papers, 2021–2026 · strength 0.76
  8. Stefan Hubert Boeck · 5 shared papers, 2021–2026 · strength 0.76
  9. Brigitte Kimmel · 4 shared papers, 2022–2026 · strength 0.67
  10. Friedrich Anger · 4 shared papers, 2022–2026 · strength 0.67
  11. Dirk Waldschmidt · 4 shared papers, 2021–2024 · strength 0.53
  12. Uwe Pelzer · 4 shared papers, 2021–2024 · strength 0.53
  13. Bence Sipos · 2 shared papers, 2018–2026 · strength 0.36
  14. Stephanie Berger · 2 shared papers, 2018–2026 · strength 0.36
  15. Sarah Rohlfing · 1 shared paper, 2026 · strength 0.29
  16. Steffen Ormanns · 1 shared paper, 2026 · strength 0.23
  17. Marcus Bahra · 1 shared paper, 2021 · strength 0.08
  18. Wolfgang Blau · 1 shared paper, 2021 · strength 0.08
  19. Michael Ståhl · 1 shared paper, 2021 · strength 0.08
  20. Ingo Klein · 1 shared paper, 2021 · strength 0.08
  21. Helmut Friess · 1 shared paper, 2021 · strength 0.08
  22. Michael Haas · 1 shared paper, 2017 · strength 0.05
  23. Jean‐Luc Van Laethem · 1 shared paper, 2017 · strength 0.05
  24. Paul J. Ross · 1 shared paper, 2017 · strength 0.05
  25. Bohuslav Melichar · 1 shared paper, 2017 · strength 0.05

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.